[1] Aversa F, TERENZI A, CAROTTI A. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. 1999(5)
[2] Collins R H, SHPILBERG O, DROBYSKI W R. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. 1997(2)
[3] TESHIMA J, HILL G R, PAN L. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantatioan. 1999(3). doi:10.1172/JCI7111
[4] Hattori K, HIRANO T, OSHIMI K. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic bone marrow transplantation, 2000(5-6)
[5] Teshima T, MACH N, HILL G R. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. 2001
[6] LINK C J, SEREGINA T, TRAYNOR A. Cellular suicide therapy of malignant disease. 2000(3). doi:10.1634/stemcells.18-3-220
[7] Taylor P A, LEES C J, BLAZAR B R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality, 2002
[8] Glass B, UHAREK L, ZEIS M. Graft-versus-leukemia activity can be predicted by natural cytotoxity against leukemia cells. 1996(2). doi:10.1046/j.1365-2141.1996.4941035.x
[9] GOULMY E, SCHIPPER R, POOL J. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. 1996(5). doi:10.1056/NEJM199602013340501
[10] Blazar B R, TAYLOR P A, PANOSKALTSIS-MORTARY A. Rapamycin inhibits the generation of graft-versus-host disease and graft-versus leukemia of Th1 or Th1 cytotoxic cytokines. 1998(11)
[11] Alyea E P, SOIFFER R J, CANNING C. Toxicity and efficacy of defined dozes of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplantation. 1998
[12] HERRAD B, STEFAN N, THOMAS B. Kinetics of the graft-versus-leukemia response after donor lymphocyte infusion for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation, 1998
[13] Nieda M, NICOL A, KIKUCHI A. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cell with cytotoxic activity against leukemia cells from patients with chronic myeloid leukemia, 1998
[14] KUMMAR S, LSBII A, YANG H K. Modulation of graft-versus-tumor effects in a murine allogeneic bone marrows transplantation model by tumor-derived transforming growth factor-β1, 2001
[15] UENO N T, RONDON G, MIRZA N Q. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. 1998(3)
[16] EIBL B, SCHWAIGHOFER H, NACHBAUR D. Evident for a graft-versus-tumour effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer, 1996
[17] MASCARDO F, MARTINEZ J A, SANZ G F. Graft-versus-tumor effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. 2000(2). doi:10.1046/j.1365-2141.2000.02368.x
[18] MARTOLA J, ALBRIIN N, ASCHAN J. A graft-versus-colonic effect of allogeneic stem cell transplantation. 2001(12). doi:10.1038/sj.bmt.1703287
[19] Childs R, CLAVE E, TISDALE J. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant:evidence for a graft-versus-tumor effect. 1999(7)
[20] Childs R, CHERNOFF A, CONTENTIN N. Regression of metastastic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. 2000(11). doi:10.1056/NEJM200009143431101
[21] BREGNI M, DODERO A, PECCATORI J. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. 2002(11). doi:10.1182/blood.V99.11.4234
[22] Rini B I, ZIMMERMAN T M, GAJEWSKI T F. Allogeneic peripheral blood stem cell ransplantation for metastatic renal cell carcinoma. 2001(4)
[23] Rini B I, ZIMMERMAN T, STADLER W M. Allogeneic stem-cell transplantation of enal cell cancer after nonmyeloablative chemotherapy:feasibility,engraftment,and clinical results. 2002(8). doi:10.1200/JCO.2002.08.068
[24] BAY J O, CHONFI B, POMEL C. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. 2000(6). doi:10.1038/sj.bmt.1702206
[25] Bishop M R. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. 2003. doi:10.3816/CBC.2003.n.010 |
